LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the following upcoming conferences in New York City:

  • Citi 2013 Global Healthcare Conference – Monday, February 25, 2013 at 3 p.m. EST. A corresponding audio webcast of this presentation can be accessed by visiting:


  • RBC Capital Markets 2013 Healthcare Conference - Tuesday, February 26, 2013 at 2:05 p.m. A corresponding audio webcast of this presentation can be accessed by visiting:


The presentations are scheduled to take place in a fireside chat format in which Daniel Passeri, President and Chief Executive Officer, will provide a brief overview of the Company's business strategy and pipeline of small molecule targeted cancer drug candidates, after which an equity analyst will moderate a question and answer session.

The audio webcasts will be archived shortly after the live events and available for 30 days following the conference.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.

The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347

For More Information:
Michael P. Gray
Chief Financial Officer
Curis, Inc.